Tumefactive demyelination presenting during bevacizumab treatment

Autor:	Claire M Rice, James C. Stevens, Clare Bailey, David Rossiter, Janev Fehmi, Neil J Scolding, Shelley Renowden, Nicki Cohen
Rok vydání:	2015
Předmět:	medicine.medical_specialty genetic structures Bevacizumab Treatment outcome Angiogenesis Inhibitors Article Tumefactive demyelination medicine Humans Intravitreal bevacizumab Child Neuromyelitis optica business.industry Follow up studies Treatment options General Medicine medicine.disease Dermatology Choroidal Neovascularization eye diseases Surgery Treatment Outcome Choroidal neovascularization Intravitreal Injections Female sense organs medicine.symptom business Demyelinating Diseases Follow-Up Studies medicine.drug
Zdroj:	BMJ Case Reports. :bcr2015212173
ISSN:	1757-790X
DOI:	10.1136/bcr-2015-212173
Popis:	We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d51c3d3e75c1931506ce3acd863074cd https://doi.org/10.1136/bcr-2015-212173 Zobrazit plný text záznamu